Unbiased Analysis of Today's Healthcare Issues
Last month, the Office of Health Economics published a report titled “Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?” I summarize some of the key challenges and solutions below. Challenge #1: Initial assessment of clinical effectiveness. Since gene therapies often target rare disease, the sample size from clinical trials is often…
Is telehealth over before it began? Let’s hope not. First, there is the clinical aspect. While telehealth was vital during the pandemic, it is unclear to what degree telehealth can fully substitute for in-person care (see Hatef et al. 2022). Likely telehealth is superior to in-person visits for some types of care, inferior for others,…
Health outcomes have improved in the US over the last 25 years. Clearly public health initiatives (e.g., reduced smoking rates) is having an impact, but another key key question is, what is medical technologies are driving these gains? Is it new surgical techniques, better diagnostics, improved medical devices, or new pharmaceuticals? This answer is difficult…
It stands to reason that policies that aim to reduce drug prices or squeeze life science companies profits are likely to decrease incentives to finance the research and development needed to bring a drug to market. Previous estimates claim that bringing a new drug to market may cost over $2 billion, and life science companies…
This is the question that a recent paper by Chorniy et al. (2020) attempt to answer. This issue is clearly very relevant as the UK recently has approved the Pfizer/BioNTech vaccine for COVID-19 before the US. Unlike most studies that attempt to examine the relationship between FDA review time and R&D investment dollars, the authors…
That is the finding from a recent paper by myself and co-authors Joanna MacEwan, Syvart Dennen, Rebecca Kee, Farzad Ali, and Katharine Batt. An excerpt from the paper is below: Between 2000 and 2016, deaths per 100,000 population across the 15 most common tumor types declined by 24%. Additionally, 10.2 new indications were approved per…
In a world with COVID-19, what factors are most influential to a company’s stock price? Are company specific or macroeconomic factors most important? It turns out, the speed of health care innovation in fighting COVID-19 may be the biggest single factor influencing all stock market prices. Barrons: General Electric stock was racing higher Tuesday, but…
Of course, clinical trials demonstrate whether a drug is efficacious or not, but are new drugs effective in the real world on average? Have they improved health outcomes at the country level? And do they provide good value? A series of recent paper by Frank Lichtenberg (see Lichtenberg 2019, Lichtenberg 2020a, Lichtenberg 2020b) aims to…
What are digital therapeutics? What evidence is needed to support their value? How should we pay for them? I participated in Academy of Managed Care Pharmacy (AMCP) Partnership Forum: Digital Therapeutics which took place in September 2019. The findings from that forum are presented in a recent JMCP article. An excerpt from the article is…
Perhaps the answer is yes according to research from Frank Lichtenberg. Every year, according to Lichtenberg’s research, drugs launched since 1982 are adding 150 million life-years to the lifespans of people in 22 countries that he analyzed. He calculated the average pharmaceutical expenditure per life-year saved at $2,837 — a bargain, he says.“According to most…